EF Hutton Reiterates Buy on Medalist Diversified REIT, Maintains $1.25 Price Target
EF Hutton analyst Gaurav Mehta reiterates Medalist Diversified REIT (NASDAQ:MDRR) with a Buy and maintains $1.25 price target.
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 167 companies set new 52-week lows.
EF Hutton Maintains Buy on Medalist Diversified REIT, Lowers Price Target to $1.25
EF Hutton analyst Gaurav Mehta maintains Medalist Diversified REIT (NASDAQ:MDRR) with a Buy and lowers the price target from $1.5 to $1.25.
OPKO Health And 2 Other Penny Stocks Are Aggressively Buying
US crude oil futures traded higher on Friday. Investors, meanwhile, focused on some notable insider trades.
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Benzinga Announces This Week’s All Access Guests
Benzinga is thrilled to announce the guest lineup for our next All Access show, presented by RedChip, set to air Friday, January 28 at 9:15 am ET.
The Lineup
9:15 am: Opening Remarks with RedChip
EF Hutton Initiates Coverage On Medalist Diversified REIT with Buy Rating, Announces Price Target of $1.5
EF Hutton analyst Gaurav Mehta initiates coverage on Medalist Diversified REIT (NASDAQ:MDRR) with a Buy rating and announces Price Target of $1.5.
61 Biggest Movers From Yesterday
Gainers
Genprex, Inc. (NASDAQ: GNPX) shares surged 167.2% to settle at $3.50 on Monday. The FDA granted Fast Track Designation for Genprex’s lead drug candidate, Reqorsa Immunogene combination therapy.
35 Stocks Moving In Monday’s Mid-Day Session
Gainers
Immix Biopharma, Inc. (NASDAQ: IMMX) shares climbed 110.3% to $7.32. The FDA granted Rare Pediatric Disease (RPD) designation to newly listed Immix Biopharma's IMX-110 for rhabdomyosarcoma, a form of pediatric cancer.
